Sanofi India demerger history
NSE: SANOFIBSE: 500674Pharmaceuticals & BiotechnologySmall Cap
Sanofi India Limited · Formerly Aventis Pharma · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1984 on BSE, May 2003 on NSE
Last close ₹2,992.00down ₹83.00 (2.70%)BSE ₹2,991.15
Share price at the NSE close on 28 Oct 2026. Previous close ₹3,075.00.
28 Oct: open ₹3,080.00, high ₹3,080.00, low ₹2,985.40
52-week range of traded prices to 28 Oct 2026
₹2,758.20Low, 23 Oct 2026₹4,898.00High, 29 Oct 2025
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,891 Cr614th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.28
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 4.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 40.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 54.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Jun 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,82442.5% delivered
Sanofi India has made no bonus issue or split since Jan 2007; its other changes to its shares on record are below.
Demergers
Every one on record, latest first.
- Demerger · 13 Jun 2024 · record date 13 Jun 2024Part of the business became a separate listed company.Price factor0.6255
A demerger's price factor is the opening price on the ex-date over the previous close. The price chart shows earlier closes multiplied by it, with the demerger reinvested; returns show the share as it traded, and beside them the same return with the demerger reinvested. Reinvested means the value of the shares of the company that was split off is treated as put back into this share at its opening price on the ex-date.